N,N Dimethylacetamide a drug excipient that acts as bromodomain ligand for osteoporosis treatment

N,N Dimethylacetamide a drug excipient that acts as bromodomain ligand for osteoporosis treatment

N,N-Dimethylacetamide (DMA) is a water-miscible solvent, FDA approved as excipient and therefore widely used as drug-delivery vehicle. As such, DMA should be devoid of any bioactivity. Here we report that DMA is epigenetically active since it binds bromodomains and inhibits osteoclastogenesis and inflammation. Moreover, DMA enhances bone regeneration in vivo. Therefore, our in vivo and in vitro...

Dimethylacetamide a drug excipient that acts as bromodomain ligand for osteoporosis treatment

Thrombospondin-1 acts as a ligand for CD148 tyrosine phosphatase.

CD148 is a receptor-type protein tyrosine phosphatase that is expressed in several cell types, including vascular endothelial cells and duct epithelial cells. Growing evidence demonstrates a prominent role for CD148 in negative regulation of growth factor signals, suppressing cell proliferation and transformation. However, its extracellular ligand(s) remain unknown. To identify the ligand(s) of...

Poly Drug Use - A Challenge for Drug Treatment

Poly-drug use refers to the use of two or more substances at the one time or repeatedly. It is common among both recreational and regular drug users across the world. Poly-drug use is a great contributor to the global number of deaths related to drug overdose. In this case, the likelihood of drug overdose and its pertaining complications in an individual is higher especially when benzodiazepine...

New allergy drug excipient allergy

Background Because of its rarity, drug excipients allergy is often unsuspected by the doctors. Some times the active drug is blamed and discontinued unnecessarily when the real culprit is drug excipients. This was suspected when patients reported exacerbation of urticaria with anti histaminic which are actually used for treating urticaria. After suspecting drug excipient as the cause of allergy.